目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY
1.1 OVERVIEW

2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 HIGH PREVALENCE OF ANEMIA AND OTHER BLOOD DISORDERS
4.2.2 GROWING NUMBER OF ACCIDENTS & TRAUMA CASES
4.2.3 RISING DEMAND FOR DIAGNOSTIC PROCEDURES
4.3 RESTRAINTS
4.3.1 INJURY CAUSED DURING BLOOD COLLECTION
4.3.2 STRINGENT GOVERNMENT POLICIES
4.4 OPPORTUNITIES
4.4.1 GROWING GOVERNMENT INITIATIVES

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE APAC BLOOD COLLECTION MARKET
5.3.1 IMPACT ON MAKET GROWTH
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON PRODUCTION

6 ASIA-PACIFIC BLOOD COLLECTION MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 BLOOD COLLECTION TUBES
6.2.1 BY FORM
6.2.1.1 VACUUM
6.2.1.2 NON-VACUUM
6.2.2 BY TYPE
6.2.2.1 SERUM-SEPARATING TUBES
6.2.2.2 EDTA TUBES
6.2.2.3 HEPARIN TUBES
6.2.2.4 GLUCOSE TUBES
6.2.2.5 PLASMA-SEPARATING TUBES
6.2.2.6 OTHERS
6.3 NEEDLES & SYRINGES
6.4 BLOOD BAGS
6.5 BLOOD COLLECTION DEVICES
6.6 LANCETS
6.7 OTHERS

7 ASIA-PACIFIC BLOOD COLLECTION MARKET, BY METHOD
7.1 OVERVIEW
7.2 MANUAL BLOOD COLLECTION
7.3 AUTOMATED BLOOD COLLECTION
?

8 ASIA-PACIFIC BLOOD COLLECTION MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTICS
8.3 TREATMENTS

9 ASIA-PACIFIC BLOOD COLLECTION MARKET, BY END USER
9.1 OVERVIEW
9.2 DIAGNOSTIC & PATHOLOGY LABORATORIES
9.3 HOSPITALS & CLINICS
9.4 BLOOD BANKS
9.5 OTHERS

10 ASIA-PACIFIC BLOOD COLLECTION MARKET, BY COUNTRY
10.1 OVERVIEW
10.2 INDIA
10.3 JAPAN
10.4 SINGAPORE
10.5 MALAYSIA
10.6 SOUTH KOREA
10.7 AUSTRALIA & NEW ZEALAND
10.8 REST OF ASIA-PACIFIC

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE ASIA-PACIFIC BLOOD COLLECTION MARKET
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE ASIA-PACIFIC BLOOD COLLECTION MARKET
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.5.1 EXPANSION
11.6 FINANCIAL MATRIX
11.6.1 SALES (USD MILLION), 2022
11.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022

12 COMPANY PROFILES
12.1 QUEST DIAGNOSTICS INCORPORATED
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ICU MEDICAL
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 KAWASUMI LABORATORIES AMERICA
12.3.1 COMPANY OVERVIEWS
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 HAEMONETICS CORPORATION
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 NIPRO MEDICAL CORPORATION
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 BECTON, DICKINSON, AND COMPANY
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 MEDTRONIC PLC
12.7.1 COMPANY OVERVIEW
12.7.2 MEDTRONIC PLC: FINANCIAL OVERVIEW SNAPSHOT
12.7.3 MEDTRONIC PLC: PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 TERUMO MEDICAL CORPORATION
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 FRESENIUS KABI AG
12.9.1 COMPANY OVERVIEW
12.9.2 PRODUCTS OFFERED
12.9.3 KEY DEVELOPMENTS
12.9.4 KEY STRATEGIES
12.10 GRIFOLS S.A
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES

13 APPENDIX
13.1 REFERENCES
13.2 ASSOCIATION OF INDIAN MEDICAL DEVICE INDUSTRY (AIMED)
13.3 INTERNATIONAL SOCIETY OF BLOOD TRANSFUSION (ISBT)
13.4 INDIAN RED CROSS SOCIETY
13.5 NATIONAL BLOOD TRANSFUSION COUNCIL (NBTC)
13.6 THE JAPANESE RED CROSS SOCIETY (JRCS)
13.7 SINGAPORE RED CROSS SOCIETY
13.8 ASSOCIATION OF MALAYSIAN MEDICAL INDUSTRIES (AMMI)
13.9 MEDICAL TECHNOLOGY ASSOCIATION OF AUSTRALIA (MTAA)
13.10 NEW ZEALAND BLOOD SERVICE (NZBS)
13.11 JAPAN BLOOD PRODUCTS ORGANIZATION
13.12 RELATED REPORTS
?